S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
Positive News Sentiment  
NASDAQ:ENLV

Enlivex Therapeutics - ENLV News Today

$3.53
-0.04 (-1.12%)
(As of 03/27/2023 02:21 PM ET)
Add
Compare
Today's Range
$3.53
▼
$3.58
50-Day Range
$3.55
▼
$4.55
52-Week Range
$3.42
▼
$8.64
Volume
3,515 shs
Average Volume
24,800 shs
Market Capitalization
$64.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Get Enlivex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.


ENLV Media Mentions By Week

ENLV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ENLV
News Sentiment
▼
1.77

0.69
▲
Average
Medical
News Sentiment

ENLV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ENLV Articles
This Week
▼
1

1
▲
ENLV Articles
Average Week

SourceHeadline
finance.yahoo.com logoEnlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers
finance.yahoo.com - March 20 at 10:17 AM
finance.yahoo.com logoEnlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial
finance.yahoo.com - February 23 at 9:51 AM
finance.yahoo.com logoEnlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS
finance.yahoo.com - February 15 at 1:03 PM
msn.com logoEnlivex cleared to expand clinical trial for cell therapy candidate
msn.com - January 25 at 1:41 PM
reuters.com logoENLV.O - | Stock Price & Latest News | Reuters
reuters.com - January 21 at 7:41 PM
ca.finance.yahoo.com logoEnlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
ca.finance.yahoo.com - January 4 at 2:16 PM
finance.yahoo.com logoEnlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
finance.yahoo.com - January 4 at 9:16 AM
uk.finance.yahoo.com logoWhat's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
uk.finance.yahoo.com - December 6 at 9:02 AM
finance.yahoo.com logoEnlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
finance.yahoo.com - December 5 at 6:00 PM
finance.yahoo.com logoFirst Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
finance.yahoo.com - December 2 at 12:09 PM
benzinga.com logoFDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies
benzinga.com - November 29 at 2:24 PM
finance.yahoo.com logoEnlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
finance.yahoo.com - November 28 at 6:21 PM
benzinga.com logoEnlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor Treatment
benzinga.com - November 15 at 10:03 AM
benzinga.com logoEnlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatment
benzinga.com - November 15 at 10:03 AM
finance.yahoo.com logoEnlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
finance.yahoo.com - November 15 at 10:03 AM
finance.yahoo.com logoHere's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
finance.yahoo.com - November 11 at 10:59 AM
finance.yahoo.com logoEnlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer
finance.yahoo.com - November 10 at 6:51 PM
benzinga.com logoA Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
benzinga.com - November 1 at 10:36 AM
proactiveinvestors.com logoEnlivex Therapeutics says strong cash runway will support progress of its immunotherapy candidate
proactiveinvestors.com - October 25 at 8:20 AM
nasdaq.com logoWe Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
nasdaq.com - October 7 at 3:53 PM
finance.yahoo.com logoEnlivex to Present at the 4th Macrophage-Directed Therapies Summit
finance.yahoo.com - October 3 at 8:35 AM
morningstar.com logoEnlivex Therapeutics Ltd ENLV Stock Chart
morningstar.com - September 16 at 7:22 PM
finance.yahoo.com logoEnlivex to Present at Upcoming Investor and Media Conferences
finance.yahoo.com - September 13 at 9:21 AM
finance.yahoo.com logoEnlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
finance.yahoo.com - September 12 at 8:40 AM
finance.yahoo.com logoEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy
finance.yahoo.com - September 6 at 9:50 AM
finance.yahoo.com logoEnlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
finance.yahoo.com - August 29 at 12:24 PM
investing.com logoEnlivex Therapeutics Ltd. Misses Q2 EPS by 9c
investing.com - August 24 at 9:12 AM
finance.yahoo.com logoEnlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
finance.yahoo.com - August 24 at 9:12 AM
finance.yahoo.com logoEnlivex Announces Second Quarter 2022 Financial Results and Provides a Business Update
finance.yahoo.com - August 22 at 8:46 AM
ca.finance.yahoo.com logoEnlivex Therapeutics Ltd. (ENLV)
ca.finance.yahoo.com - August 19 at 8:35 PM
finance.yahoo.com logoEnlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
finance.yahoo.com - August 17 at 12:26 PM
finance.yahoo.com logoEnlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™
finance.yahoo.com - August 3 at 12:55 PM
finance.yahoo.com logoSheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
finance.yahoo.com - July 6 at 9:05 AM
benzinga.com logoReprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders
benzinga.com - June 23 at 4:46 PM
finance.yahoo.com logoEnlivex to Present at the 2022 Jefferies Healthcare Conference
finance.yahoo.com - June 7 at 8:48 AM
seekingalpha.com logoEnlivex gets Israeli nod to start phase 1/2 Allocetra trial for treating peritoneal cancer
seekingalpha.com - June 6 at 12:46 PM
finance.yahoo.com logoEnlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
finance.yahoo.com - June 6 at 12:46 PM
finance.yahoo.com logoWe Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
finance.yahoo.com - June 4 at 6:52 PM
finance.yahoo.com logoWe Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
finance.yahoo.com - June 4 at 6:52 PM
finance.yahoo.com logoEnlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 31 at 9:27 AM
finance.yahoo.com logoEnlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients
finance.yahoo.com - May 25 at 8:11 AM
morningstar.com logoEnlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman | Morningstar
morningstar.com - May 24 at 9:35 PM
finance.yahoo.com logoEnlivex to Present at the H.C. Wainwright Global Investment Conference
finance.yahoo.com - May 19 at 9:00 AM
finance.yahoo.com logoEnlivex Announces Upcoming May Conference Presentations
finance.yahoo.com - May 10 at 10:44 AM
finance.yahoo.com logoEnlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting
finance.yahoo.com - May 9 at 2:00 PM
seekingalpha.com logoEnlivex gets 2 US patents for treating sepsis with cell therapy Allocetra
seekingalpha.com - May 5 at 9:32 AM
finance.yahoo.com logoEnlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra
finance.yahoo.com - May 5 at 9:32 AM
benzinga.com logoHC Wainwright & Co. Maintains Buy on Enlivex Therapeutics, Lowers Price Target to $15
benzinga.com - May 2 at 9:28 AM
finance.yahoo.com logoEnlivex Announces Upcoming Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 2 at 9:28 AM
seekingalpha.com logoEnvilex Therapeutics reports FY results
seekingalpha.com - May 1 at 9:25 AM
Get Enlivex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ENLV) was last updated on 3/27/2023 by MarketBeat.com Staff